Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin vs Observation in DLBCL after R-CHOP
NCT01510184Phase 3Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Apr 2012
- Primary completion
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Spectrum Pharmaceuticals, Inc.. Started Apr 2012; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01510184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01510184.